N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 4 N=22 Targeting Right Ventricle in Pulmonary Hypertension Gilead
Pulmonary Hypertension
Primary: Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage) — 7.56; -3.99 percentage
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
Phase 4 N=22 Targeting the Right Ventricle in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction — 5.8; -4.7; 0.49 percentage
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
N/A N=25 CentriMag RVAS U.S. Post-approval Study Protocol
Right Ventricular Failure
Primary: Survival — 80 percentage of survival at 30 days
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=23 Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA
Obstructive Sleep Apnea · Chronic Obstructive Pulmonary Disease · Overlap Syndrome
Primary: Right Ventricular Remodeling Index — 0.3747; 0.2817 ratio
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
Phase 4 N=87 REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26 — 15.17 milliliters (mL)
N/A N=248 Real-time Effort Driven VENTilator Management
Ventilation Therapy; Complications · Diaphragm Disease · Pediatric Respiratory Diseases
Primary: Median Duration of Weaning — 0.09; 1.04; 2.03; 2.10 days — p=.045
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Phase 1 N=21 Sildenafil in Single Ventricle Patients
Heart Disease
Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL
Phase 2 N=25 Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD
Tetralogy of Fallot · Pulmonary Insufficiency
Primary: Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Size Compared to MRI Derived Values. — 187.1; 175.4; 205.0; 86.0 ml
Phase 3 N=45 RELOVAIR® Lung Deflation Study
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVI) at the End of the Overall Treatment Period — -0.47; 5.35 Milliliter per meter square…
N/A N=98 ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction
Bradycardia
Primary: LVEF — 64.22; 63.14; 59.96 % LVEF — p=0.1734
Phase 3 N=26 The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
Precapillary Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention — -2.8; 3.9 percentage of ejected blood — p=0.008
Phase 2 N=201 A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Hypertension, Pulmonary · Ventricular Dysfunction, Left
Primary: Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16 — -6.1; -0.8; -4.5; -4.0 mmHg — p=0.1044
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
Phase 4 N=605 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement
Cardiovascular Diseases
Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72
N/A N=134 Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Bradycardia
Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
Phase 2 N=9 Improving Right Ventricular Function in Young Adults Born Preterm
Infant,Premature
Primary: Right Ventricular Energetic Efficiency Pre and Post Metoprolol — 15.5; 12.7 µJ/ml — p=0.004
N/A N=67 TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
Right Ventricular Dysfunction
Primary: 3D RVEF (Baseline) — 44.71; 48.74; 49.11 percentage — p=0.0167
N/A N=17 REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
Ventricular Tachycardia
Primary: Freedom From First Event Requiring ICD Therapy — 62.5; 50; 62.5; 37.5 probability of freedom
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110